Psoriasis Vulgaris
Conditions
Keywords
Psoriasis, Botulinum toxin
Brief summary
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
Interventions
BIOLOGICALinjection of botulinum toxin type A.
35 to 100 units injected around a skin lesion (plaque) one time.
Sponsors
Allergan
University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Healthy subjects. Psoriasis vulgaris diagnosis made by a board certified dermatologist involving at least one area that has been intolerant or recalcitrant to at least two forms of recognized topical or systemic treatments in the past. In addition, the subject should have at least a score of 2 for keratoderma and erythema. Signed informed consent. Willing to adhere to protocol.
Exclusion criteria
* Immunosuppressed patients, pregnant, secondary skin infections, phototherapy within 4 weeks of the botulinum toxin injection, exposure to any topical or systemic retinoid treatment with the last 12 months, volunteers taking chloroquine and hydroxychloroquine, volunteers on warfarin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| psoriasis scoring scale | baseline and 3months |
Secondary
| Measure | Time frame |
|---|---|
| 3mm skin biopsy. | baseline and at 3 months. |
Countries
United States
Outcome results
None listed